Porges sees the pros — and cons — for Biogen in Lilly’s Alzheimer’s snafu; Idera forges development pact; UK government adds more cash for R&D programs
Leerink’s Geoffrey Porges had some good news and some bad news to relate to Biogen $BIIB on Friday. The good news is that Eli Lilly’s flop heard round the world on Alzheimer’s with their latest Phase III for solanezumab means that a success for aducanumab would be worth much, much more now in terms of potential revenue, now that the pharma giant is out of the game. The bad news: Now that Lilly $LLY has thrown even more cold water on the amyloid beta theory behind the memory-wasting disease, aducanumab is far less likely to succeed — even though it’s a distinctly different program. Porges cut his probability of success from a quite high 65% to a quite low 35%.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
